# Transcranial Alternating Current Stimulation for Pain: Mixed Evidence and the Path to Precision Neuromodulation

**Authors:** Yaser Fathi, Amin Dehghani, David M. Gantz, Giulia Liberati, Tor D. Wager

PMC · DOI: 10.3390/brainsci16020152 · Brain Sciences · 2026-01-29

## TL;DR

This review explores how transcranial alternating current stimulation (tACS) affects pain perception, finding mixed results and suggesting personalized approaches could improve its effectiveness.

## Contribution

The paper proposes integrating new tACS methods like phase-specific stimulation and individualized modeling to achieve more precise and personalized pain modulation.

## Key findings

- Out of 14 studies, 8 showed analgesic benefits or neural changes with tACS.
- Somatosensory alpha oscillations were most commonly targeted in tACS pain studies.
- Variability in stimulation protocols and individual differences may explain inconsistent results.

## Abstract

Neural oscillations are fundamental to the integration of sensory, affective, and cognitive processes that contribute to pain perception. Transcranial alternating current stimulation (tACS) provides a valuable tool for investigating and modulating these oscillatory dynamics. In this review, we examine the effects of tACS on pain perception and pain-related oscillations in both healthy participants and individuals with chronic pain, highlighting methodological variability and mechanistic uncertainties that may contribute to mixed findings. We identified 14 studies, including 9 studies of experimental pain in healthy individuals and 5 of clinical pain disorders, comparing tACS to sham. Somatosensory alpha was the most frequently targeted oscillatory feature. Results varied considerably. Several studies reported reductions in pain, increases in alpha power, or changes in sensorimotor and prefrontal connectivity, but others showed no meaningful neural or behavioral effects. Out of the 14 studies, 6 demonstrated analgesic benefits and 2 showed improvements only under specific conditions or within subgroups, for a total of 8/14 studies with positive findings. Possible sources of heterogeneity include variation in stimulation duration, electrode montage, frequency alignment with individual rhythms, contextual state, and anatomical and neurophysiological differences across individuals. Pre-registered studies with sufficient power are needed to replicate effects within the most promising intervention protocols to establish a foundation in the field. We also recommend inclusion of brain imaging or electrophysiological recordings to verify whether stimulation effectively modulates the targeted neural oscillations. Finally, recent methodological advances, including phase-specific tACS, amplitude-modulated tACS, and individualized electric-field modeling, offer new opportunities to enhance mechanistic precision and clinical applicability. We argue that by integrating these approaches, future research can move beyond fixed, one-size-fits-all protocols toward personalized, state-dependent, closed-loop tACS approaches. Exploring these frontiers will transform tACS from an exploratory tool into a reliable intervention for pain.

## Full-text entities

- **Genes:** DPYSL2 (dihydropyrimidinase like 2) [NCBI Gene 1808] {aka CRMP-2, CRMP2, DHPRP2, DRP-2, DRP2, N2A3}, GRIN2B (glutamate ionotropic receptor NMDA type subunit 2B) [NCBI Gene 2904] {aka DEE27, EIEE27, GluN2B, MRD6, NMDAR2B, NR2B}, BCL2A1 (BCL2 related protein A1) [NCBI Gene 597] {aka ACC-1, ACC-2, ACC1, ACC2, BCL2L5, BFL1}, SM1 (Schistosoma mansoni, susceptibility/resistance to) [NCBI Gene 7911]
- **Diseases:** analgesia (MESH:D000699), chronic (MESH:D002908), itching (MESH:D011537), chronic low back pain (MESH:D017116), TIS (MESH:C536956), Cognitive Impairment (MESH:D003072), hyperactivity (MESH:D006948), hyperalgesia (MESH:D006930), migraine (MESH:D008881), hypersensitivity (MESH:D004342), tingling (MESH:D010292), Chronic Pain (MESH:D059350), depressive symptoms (MESH:D003866), neuropathic pain (MESH:D009437), Anxiety (MESH:D001007), essential tremor (MESH:D020329), nociceptive pain (MESH:D059226), Fibromyalgia (MESH:D005356), tremor (MESH:D014202), Pain (MESH:D010146), pain disorders (MESH:D013001), injury to (MESH:D014947)
- **Chemicals:** capsaicin (MESH:D002211), PAF (-)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Macaca mulatta (rhesus macaque, species) [taxon 9544]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938538/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938538/full.md

## References

77 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938538/full.md

---
Source: https://tomesphere.com/paper/PMC12938538